The application of biotechnology is a potential tool for mitigating the present and future fooding and clothing demands in developing countries like India. The commercialization of biotechnological products might benefiting the poor's in developing countries are unlikely to be developed. Biotechnology has the potential to provide a wide range of products and the existing production skills in the industrial, pharmaceuticals and the agricultural sector.
INTRODUCTION
Biotechnology is a popular term for the generic technology of the 21 st century. Recent technologies like genetic engineering and recombinant technology now included along with the old biotechnology concept. Earlier nobody thought that biotechnology could manipulate, plant, animal, microbes or human being. So no one thought of the need for evolving a comprehensive law and regulation for biotechnology product and process *Address correspondence to this author at the Department of Environmental Science, University of Kalyani, Kalyani, Nadia, West Bengal-741235, India; Tel: +91-33-2580 8749; Fax: +91-33-2580 8749; E-mail: scsantra@yahoo.com? es. Now biotechnology has progressed in various generations and this field mandated a comprehensive legal framework for proper regulation. It is focusing on the manipulating of living or biological active materials at molecular level in scientific and commercial way. There are so many applications of modern biotechnology in the field of food, health, energy and environment. Research in biotechnology is extremely time consuming and requires huge investment. Granting of the Intellectual Property Rights (IPR) is an effective tool to protect the biotechnology inventions. Department of Biotechnology, Govt. of India survey the Indian patents in biotechnology during 1972-1988 and Subhas C. Santra showed that patenting in biotechnology is foreigndominated with nearly 75% of the patents owned by foreigners. Pharmaceutical patents covered the processes for the preparation of antibiotics, vitamins, enzymes, antibodies and vaccines. The agricultural sector covers plant growth regulators, veterinary vaccines, plant cells and tissue culture. In the food industry, dairy and fish products, yeast and food additives, starch products, glucose and fructose syrups are covered by the biotechnology patents [1] .
Many Indian biotechnology companies have developed proprietary processes for manufacturing 'bio-generics' or 'bio-similar', derivative forms of first generation. A genetically engineered microorganism was granted patent, in the field of biotechnology gained enormous significance on genetically engineered plant and human genetic material. The global adoption of the patent system started in Venice as the first patent law was enacted in 1494, which regarded as the foundation for the world's patent system. The requirements such as utility, novelty and non-obviousness are still the basis of modern patent law around the world. India is the one that has immense potential to utilize biotechnology to its advantage to solve some of its most intractable problems of productivity, health and environment.
The patentability of genes and other nucleic acid sequences is justified on the ground that they have been subject to a microbiological or non-biological process, i.e., gene sequencing, which is itself a standard process patentable and patented under existing patent laws for invention. The patenting of genomes raises the question of the function of the genomes. The genome can do nothing by itself, while its function in the organism cannot be considered separately from the totality of the organism.
Patents have generally been recognized as a measure of innovative activity in different technological fields. Biotechnology patents are related to inventiveness; the area of genetic modification, however, poses a challenge to relate the raw patent data with commercial technology. Different aspects of research, like genetic constructs, transformation tools as well as utility patents of genetically modified organism contribute to this field. A clear understanding of the underlying facts and inputs in the innovation process in biotechnology sector is necessary to gain appropriate insight into the relationship between patents and other inputs within the framework of economic policies and regulatory processes leading to commercialisation of new technologies [2] .
BIOTECHNOLOGY PATENT IN INDIA
A patent is an exclusive right granted by the government to an inventor for a limited period of time. It is granted by the patent office in which you wish to protect your valuable invention. It covers each and every area of technology such as pencil to helicopter [3] . The advent of biotechnology necessitated the law of patent should be suitably modified to match the needs of science and technology. The industries that utilise biotechnology are convinced that intellectual property protection should be obtainable for the inventions that stem from research and which have commercial value. The biotechnology research workers in academic institutions increasingly share this view because of their need for research funding which is in part conditional on patentability. But many people are not in favour of patents in biotechnology because they believe 'patenting life' is unethical in principle. Inventions relating to biotechnology have also been rather controversial in India.
The framing of a common law or rules for biotechnology patent is a complex process as the field biotechnology is divided into different sub fields. Those sub fields like genomics, tissue culture of plants and animals which have unique characteristics. The properties, applications, processes and products in different area of biotechnology are also different from each other.
The Biotechnology sector is being hailed as the sunrise sector of India. It has been making steady progress over the last few years and has the potential to emerge as a global leader in the biotech industry. During the year 2013-14, the total revenue generated in India from patent was Rs. 312.24 crore, which was 10.60% higher than that of the previous year, while total non-plan expenditure was Rs.39.63 crore leaving a revenue surplus of Rs.272.61 crores. The patent office generated a total revenue of Rs. 189.61 crore [4] . Major biotech companies India and global are given in Table 1 .
The Indian firms are not yet filing a significant number of patent applications in India. Companies generating significant biotechnology revenues in India; reveal that they filed only a handful of Indian patent applications during that period [3] .
Patents are the strongest form of intellectual property protection in the sense that they allow the rights holder to exert the greatest control over the use of patented material. The concern patent protection to biotechnology-based research is that it could lead to patenting of research tools or the grant of broad patents that could potentially block further useful research. The Trade Related Intellectual Property Rights System (TRIPS), developing countries can choose to provide patents or develop a sui generis system to protect innovations in agriculture. Under Article 27.3 (b) of the TRIPS Agreement, members of the World Trade Organisation (WTO) may exclude from patentability plants and animals and essentially biological processes for the production of plants or animals other than non-biological and microbiological processes. In Indian patent law, the Patents (Amendment) Act, 2002 introduced significant changes with regard to the patentability of biotechnological inventions. By specifically allowing for the patentability of microorganisms, the law complied with the requirement of article 27.3(b) of the TRIPS Agreement. The (TRIPS) Agreement, to which India is a party as a member of the World Trade Organization (WTO), requires some level of protection of biotechnological inventions, including of plant varieties. India has to implement most of its TRIPS obligations by end of 1999 and is currently in the process of drafting revised legislation. The post-TRIPS regime has witnessed greater investment in research and development [7] . Within pharmaceutical research and development, there has been a significant increase in the focus on novel drug discovery [8] although new dosage forms remain dominant among product patents. The patent filing activity in the Indian Patent Office has increased dramatically in recent years ( Table 2 ).
The offices under the Controller General of Patents, Design and Trademarks (CGPDTM) have reported an overall increase of around 2.16% in filling of intellectual property applications during the reporting year 2013-14 (2, 51,564) compared to the previous year 2012-13 (2, 46, 251) . During 2013-14, 42,951 patent applications ware filed. The office witnessed a marginal decrease of 1.65% in filing as compared to the previous year. The trends of last five years in respect of patent applications filed, examined, granted, refused and abandoned are given in Table 2 . India, after becoming a member of the WTO, amended the 1970 Patent Amendment Act in 1999 so as to incorporate benefits for applications from industries such as drugs and agro-chemicals and (Fig. 1) . The selected patents on the biotechnological sector granted in India given in Table 3 and the trends of filed and granted patents in biotechnology shown in Fig. 2. 
CHRONOLOGICAL DEVELOPMENT OF PATENTS IN INDIA
The force in the year 1972, amending and consolidating the existing law relating to Patents in India. The Patents Act, 1970 was again amended by the Patents (Amendment) Act, 2005, wherein product patent was extended to all fields of technology including food, drugs, chemicals and micro organisms. An invention relating to a product or a process that is new, involving inventive step and capable of industrial application can be patented in India. However, it must not fall into the category of inventions that are nonpatentable as provided under Section 3 and 4 of the (Indian) Patents Act, 1970. Patent application can be filed, either alone or jointly, by true and first inventor or his assignee in India [12] .
In India, before 2002 patents were not allowed on living entities, biological materials, processes for production of living substances including nucleic acids but patents were granted for processes of producing non living substances by chemical processes, bioconversion and microbiological processes using microorganisms or biological processes [13] . British rulers enacted the first ever patent law in India the Act VI of 1856 on protection of inventions based on the British patent law of 1852. After several modifications in 1859, 1872 and 1888, the consolidated Indian Patents and Designs Act, 1911was enacted and offered patent protection to the inventions. Judicial pronouncements in the US and EU and suitable intervention by judiciary led to amendments of patent laws in these countries. India's patent third laws were amended in 2002 to explicitly include biochemical, biotechnological, and microbiological processes within the definition of potentially patentable chemical processes. The formal bio-guidance is the need of the hour as biotechnology is gaining momentum in India.
BIOTECHNOLOGY PATENTING SYS-TEM
Biotechnology patenting systems were developed in three major areas in Agricultural, Industrial and Pharmaceuticals.
Agricultural Patents
Most of the population relies on agriculture for its livelihood. India is self-sufficient in wheat and paddy, but deficient in other agricultural produce. Agriculture in developing countries is predominantly rural based. Majority of the poor people depend on this agriculture. The new technology will improve the yield or reduce the cost of production will also directly reduce poverty and indirectly help the poor by lowering the price of food and by creating more employment opportunities. The traditionally, technical changes have occurred as on-farm experimentation such as adapting different cropping pattern, and such improvements were kept out of intellectual property protection. During the Green Revolution (GR) period in India (1960s), many hybrid and high yielding varieties were introducedparticularly in rice and wheat. These were the types of seed variety that can be replanted each year, which made GR very successful.
In India biotechnology research and development (R &D) is in progress particularly in crop improvement. The most promising benefit from genetic engineering is the use of recombinant DNA techniques. Because it is possible to break through natural species barriers systematically by moving genes from one species to another that do not combine in nature. The genetically modified (GM) crops have been developed by using input traits (e.g. resistance to insect pests and plant diseases), output traits (e.g. delayed fruit ripening, better taste, nutritious, elimination of saturated fats in cooking oils, elimination of allergens, better delivery of necessary nutrients) agronomic traits (e.g. resistance to drought, salinity, acidity, flood, etc. and increase in crop yield) [14] .
The Indian Government, through its annual budget for 2005-06, has emphasized that the main thrust on agriculture sector would be to achieve further diversification in farm activities [15] . Agricultural biotechnology research is characterised by developing genetically engineered plants that have huge impact on global food production and seed industry. Research in this sector consolidated since 1990s and attracted massive investments for R&D across several major private sector companies, public funded research laboratories and universities. Such a phenomenal technical change is not possible without path-breaking innovations at all levels evidenced by growing number of patents in agricultural biotechnology [2] .
A small agricultural biotechnology (agribiotech) company needs to establish a strong Intellectual Property (IP) portfolio. Such a portfolio provides a foundation for R&D, encourages outside investment and funding, and supports product commercialization. An important step in establishing an IP portfolio is in-licensing patent rights from third-party patent holders. Non exclusive licenses typically give a company freedom to operate and open up the possibility of creating commercializable products. Exclusive licenses give a company an exclusive position for commercialization under the patents in question. The agriculture patents constitute ~ 2% of the total Indian patents [16] . The total output of Indian patents on agriculture and food is given in Tables 4 & 5. 
Industrial Patents
To encourage inventions by promoting the protection and utilization technologies, so the industries are developed, which contribute to the promotion of technological innovation and to the transfer and dissemination of technology. Biotechnology industries are largely dominated by companies serving both the pharmaceutical and biotechnology products. Out of 362 biotechnology firms in India, 54% of the revenue comes from the top 20 companies namely Biocon, serum institute of India, Panacea Biotec, Nuziveeedu seeds, Reliance Life Sciences, Rasi seeds, Mahyco, TRansasia, Ankur seeds, Syngene International, Bharat Biotech, Krishidhan Seeds, Shantha Biotech, Novozymes, Bharat serum, Jubiliant Life Science, Siro Clinpharma, Cadila, Indian Immunologicals, and Tulip Groups. [9] In recent years, the biotech industry is highly active in protection of its IP and doing extensive research and development to overcome the current competitive market force. The overview of this activity in terms of Indian patent filing trend and their product is shown in Table 6 .
Pharmaceutical Patents
India is an important manufacturer of globally recognised high quality pharmaceutical products and has become WTO/TRIPs compliant in post-GATT period. The trends of patent grants for Indi-an pharmaceutical companies improved gradually but the numbers of companies having patents are very less compared to the total number pharmaceutical companies in India.
More than 90% of the Indian pharmaceutical industries are controlled by foreign multinationals. Drugs were manufactured outside India and imported for a higher cost. The drug prices were so high that in 1961, the US senate committee headed by Senator Estes Kefauver observed that India ranked among the highest priced nations in the world for drugs. Statistics of the first five year plan of India reveals that income from industries was as low as a mere 6.6% of the total national income. A mere 8% of the total labour force was working in industrial establishment. India was the largest reservoir epidemic diseases and it accounted for 5.1% of the total mortality. Around 50% of India's population were living under poverty and were unable to afford the cost of drugs. Consequently, life expectancy was very low and mortality rate due to diseases was very high. The central government under the Drugs Act of 1940 imported required drugs since India had local production of bulk drugs. India took significant steps to control the expenditure on drugs by signed an agreement with UNICEF to set up a factory for manufacturing of penicillin and antibiotics. This resulted in the establishment of Hindustan Antibiotic Limited in 1957 to manufacture drugs at a cheaper rate for the public. The government then appointed justice Rajagopala-Ayyangar Committee in 1957 to recommend revision to the patent law to suit industrial needs. The object of the committee was to ensure India developed a locally sustainable pharmaceutical market. The report submitted in 1959, that the patent legislation needed a clear directive. In recommending changes, the Ayyanger committee was bound by the provisions of the Indian constitution. Article 21 of the Indian constitution described right of life, which included the right to good health. The preamble of the Constitution requires policies to balance social and economic rights. Hence public health concerns need to be weighed with business interests in amending the patent legislation. The Ayyanger report argued that a patent policy vesting unrestrained monopoly would deny a vast section of India's population from access to medicines [18] . The Indian pharmaceutical industry remained import dependent till 1972, deeming most of the drugs unaffordable [19] . Political and policy developments in the early 1970's such as the new patent acts of 1972 and Drug Price Control Order (DPCO), 1970 laid the foundation for a strong pharmaceutical industry in India. Public sector focus on pharmaceutical industry and policies that curbed control of multinationals added to this conducive policy environment that led to the growth of domestic firms and establishment of India as a dominant supplier of pharmaceutical drugs across the world [20] . In the pre-TRIPs regime, the absence of product patents allowed local production of patented drugs at a fraction of the original cost while process patents encouraged generic companies to reduce the production costs of drugs. India's compliance with the TRIPS regime that became complete in 2005 has changed strategic options of Indian pharmaceutical firms. In the year 2013, the Indian pharmaceutical industry was the "third largest in the world in terms of volume" estimated to be worth $ 10 billion in 2010 [21] . The Indian pharmaceutical industry remains pivotal in providing essential drugs at affordable prices. Patented drugs, on the other hand, comprise approximately 1% of the pharmaceutical market in the country [22] .
Biotechnology is used for pharmaceuticals and drugs manufacturing through biological processes. These are some of the best drugs used today and certainly among the most expensive. The Indian pharmaceutical industry is a successful, hightechnology-based industry that has witnessed consistent growth over the past three decades. The current industry players comprise several privately owned Indian companies that have captured a substantial share in the domestic pharmaceutical market due to factors such as favourable government policies and limited competition from overseas [23] . India had a product patent regime for all inventions under the Patents and Designs Act 1911. However, in 1970, the government introduced the new Patents Act, which excluded pharmaceuticals and agrochemical products from eligibility for patents. This exclusion was introduced to break away India's dependence on imports for bulk drugs and formulations and provide for the development of a self reliant indigenous pharmaceutical industry (Table. 7 
).
Patenting inventions is one parameter that enhances the strengths of a country economic. India has emerged as a manufacturing source for high quality pharmaceuticals which are recognized and accepted globally. There is a significant improvement in patent grants for Indian pharmaceutical companies, however the number of companies with patents is very less when compared to the total number of pharmaceutical companies in India ( Fig. 3) [9].
INDIAN PATENT ACT AND POLICY IS-SUES
Patent Act in India was established in 1856 and has been modified several times. The major amendment was done in 1970 which satisfied the international norms of patentability such as novelty, inventive step and industrial application. The patent act 1970 had nothing specific about the biotechnology invention and protection. At the same time a significant number of biotech inventions and patent application were applied in the US and EU patent offices and courts as a result there was a need for the amendment of Indian patent act to introduce biotech patentability law. The amendment came in 2002 to explicitly include biochemical, biotechnological and microbiological processes within the definition of potentially patentable process [25] . 
INTERNATIONAL PATENTS CONTRO-VERSY WITH INDIAN MATERIALS
The herbal products have a significant demand in developed and developing countries. The lead pharmaceutical companies emphasized on indigenous system of medicines acquired information from traditional healers of indigenous communities. Multi-national pharmaceutical companies interact with local communities in village level to identify plants and plant materials at their local and indigenous medicinal use.
Biopiracy of Indian traditional knowledge increases because this traditional information exists in different regional language in regionally published or unpublished format. The patent offices are unable to search this information prior to granting patents.
The treatments of human diseases from traditional knowledge are time-tested since they have been in practice for long ago. The reliability of the application of traditional medicine coupled with the absence of such information with patent offices provides an opportunity for the interlopers for getting patents on these therapeutic formulations of traditional medicines. A tree legendary to India has been used as a biopesticide and medicine in India for century's. Ancient Indian Ayurvedic texts have described the Neem tree and it's medicinal properties as far back as 5000BC. The leaf extracts of Neem plant can be used for controling a lots of pests and fungal diseases. The Neem oil can be used as mixed in soap, flu control, relief from malaria, cure of skin disease and meningitis.
The European patent office granted a patent (EPO patent No.436257) in 1994 to the US Corporation W.R. Grace Company and US Department of Agriculture for a method for controlling fungi on plants by the aid of hydrophobic extracted Neem oil. In 1995, some international NGOs and representatives of Indian farmers filed legal opposition against the patent of Neem oil. They submitted evidence that the fungicidal effect of extracts of Neem seeds had been known and used for centuries in Indian agriculture to protect crops, and therefore, it should not be patentable. In the year 1999, the European patent office decided that according to the evidence all features of the present claim were disclosed to the public prior to the patent application and the patent was not considered to involve an inventive step. The patent granted on Neem was revoked by the European patent office in May 2000. In March 2006 the European patent office rejected the challenge made by the USDA and the chemicals multinational, W. R. Grace to the previous decision to cancel their patent on the fungicidal properties of the Neem seeds extract [28] .
 Turmeric (Curcuma longa Linn.)
In India the Turmeric(Haldi) has been traditionally used as medicine for centuries for the treatment of wound healing and common cold. It should not be patented in recent time for these properties of Turmeric. The rhizome of turmeric has the properties that make it an effective ingredient in medicines, cosmetics and dyes and also used as a important spice in Indian cooking. In 1995, two expatriate Indians at the University of Mississippi Medical Centre were granted a US patent (No.5, 401,504) on use of turmeric in wound healing. The Council of Scientific & Industrial Research (CSIR), India, New Delhi filed a complain with the US PTO challenging the patent on the grounds of existing of prior art. The CSIR argued that the medicinal use of Turmeric for healing wounds and rashes was not a novel invention as it has been used for thousands of years in India.Their claim was supported by documentary evidence of traditional knowledge, including ancient Sanskrit text and a paper published in 1953 in the Journal of the Indian Medical Association. Despite an appeal by the patent holders, the US PTO upheld the CSIR objections and cancelled the patent. The turmeric case was a landmark judgment as it was for the first time that a patent based on the traditional knowledge of a developing country was successfully challenged. The US Patent Office revoked this patent in 1997, after ascertaining that there was no novelty; the findings by innovators have been known in India for centuries [28] .
CURRENT AND FUTURE DEVELOP-MENT OF PATENTING IN INDIA
Recent changes in India's patent policy have led to some review of India's position on patents. The recent flow in patent applications in India provides important data for evaluating the potential for domestic sector to adjust to the new patent regime. In the last two decades, most reforms were implemented without any profound knowledge or thorough analyses of the societal and/or economic impact. The advancements in biotechnology and information technology have significant impact on patenting system. It is difficult to judge whether the patent system benefits to the society. If we did not have a patent system, it would be irresponsible, on the basis of our present knowledge of its economic consequences, to recommend instituting one. It should be recognized that there is a striking correlation between wealth, economic performance and the scope of the patent system in all affluent countries. In recent years, the patent system has been both strengthened and expanded without any evidence of the benefits to society. Priority should be given to generation, evaluation, protection and effective commercial utilisation of tangible products of intellectual property in agriculture. The policy related to protection of IPR in different sectors of technologies, attention should be given to further liberalisation of its market, promotion of private sector investment and more efficient technology systems. The R&D in the field of biotechnology should be encouraged for exploring new tools and improve the biological systems for public interest. To support the future growth and welfare the development and exchange of knowledge should be properly evaluated and secured through patent system. By increasing the R&D and manufacturing sector the number of patent filling will grow in future.
CONCLUSION
The application of modern biotechnology for agricultural, ecological and pharmaceutical sectors has great hopes for the extent to which man can explore and exploit the biological resources. So it allows for the direct genetic modification of the life forms. The commercialization of genetic modified organisms has led to intense international and multicultural conflicts and debates. Using the advance technology to modify life forms is becoming difficult for law and rules to protecting property right of biotechnological products. One of the significant developments in the patent laws has been in the Biotechnology sector. The biotechnology patents are the debating subjects that many countries consider these patents create future problems to access the patented life forms.
Most of the biotechnology processes have been invented in developed countries. Such technologies are yet to benefit the developing countries partly due to commercial reasons and also due to the fact that they may not always be applied in their present form. Development of appropriate biotechnology and their commercialization in developing countries is hindered by the array of existing patents. Such application will require the use of several patents with multiple owners. Moreover, such patents are owned by a few companies and institutions. Negotiating such 'patent thickets' poses serious challenges in development and application of biotechnology in developing countries. National and international initiatives should be taken for properly formulation of the intellectual property right law, and particularly patent law for patenting biotech products without depriving the interest of common peoples. India's domestic policy and international negotiations on one aspect of IPRs, patents, provides important lessons for formulating a comprehensive negotiating strategy on TRIPs. Support from developing countries, disunity among advanced nations and the role of NGOs were also factors that enabled India to promote its interests in the negotiations. In recent years a good number of patents are granted for all sorts of biotechnological inventions in India. The Research and Development in the field of biotechnology should be encouraged for exploring new tools and improve the biological systems for the interest of common people. Priority should be given to generation, evaluation, protection and effective commercialization of tangible products of intellectual property in agriculture, environment and medicine. Researchers in different Institutions must be aware of intellectual property issues in their research topics. The Intellectual property right has an impact on the social and economic development of a society. The policy related to protection of IPR in different sectors of technologies, attention should be given to further liberalization of its market, promotion of more efficient technology systems and private sector investments. The future growth and development in the sector of biotechnological research and exchange of knowledge should be encouraged through proper evaluation and secure patent system.
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